XtalPi Holdings (HKG:2228) expects to record a revenue of HK$250 million for 2024 reaching the revenue threshold for a commercial company, a Monday bourse filing said.
The company attributed the revenue to its drug discovery solutions, intelligent automation solutions, business development and market opportunities.